The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Management will be feeling the pinch too, as will employees many with options.
just checked my inbox and that email address below is the same one I have used, always received a reply and on one occasion a telephone call from director.
I have been assured they will submit recommendations at the next board meeting, provided these are within the general remit.
amones, its worth a shot, some replies can take a couple of weeks in my experience.
Luckily, it’s weekend and a pause for the agonising slump in the share price and diminishing market value. Regarding getting any kind of response from i.r, good luck to those trying to contact.
I will email them - the least they could do is update the out of date pipleline which was last changed in July 2023!
Investor Enquiries
ir@hutch-med.com
Its difficult to rally investors to write to companies, for what ever reason there is a block - shareholders just do not like doing it, therefore change is hard without some form of engagement.
If you have sent an email please post as it may encourage others.
Jatw, yes, treasury shares would be the way to go serving both the company and shareholders.
Wincanton just got bid for today
Wincanton to go private – with board fed up with share price underperformance
https://www.cityam.com/wincanton-to-go-private-with-board-fed-up-with-share-price-underperformance/
Appears outright deliberate act. Is there any reason for this decline this share is experiencing?
After having sold its shares in public offering, 3 years ago at HKSE, more than twice the present price, at what “attractive” price would the company be willing to buy back?
A great opportunity for a larger company to acquire
Unbelievably this is 30% off from the high hit with the FDA approval of Fruq.
Re: Buy backs, there is still much spending to be done to get to cash flow positive from sales and royalties alone, but as they dont expect to raise more capital they are likely to end up in a position where they have excess capital….but that is an issue for a few years time.
In the short term they should buy in the market as treasury shares to meet share awards to staff and Directors.
I think that resolution is always there and I can't see them doing Buybacks for years......they seem to be inept when it comes tro shareholders interests or strategic actions rto build shareholder value. Almost a vanity Project for CKHH.....
Resolution 5 of last years AGM which received almost 100% of votes cast
5. To grant a general mandate to the Directors to repurchase shares of the Company.
Here's a search of today's RNS release on share buy backs, no less than 4 pages
https://www.londonstockexchange.com/news?tab=news-explorer&headlines=76
I know there's not many on his board, but could I suggest copying above link along with a note and sending into the board for airing - if anyone needs contact details I can post here.
Given the small free float a share buy back would make a noticeable difference, this has become standard with many companies on both sides of the pond actively buying back shares.
Worth checking the LSE RNS first thing in the morning to see just how prolific it is, perhaps if a few of us on here suggest it then it may get tabled at next AGM.
It was mentioned in one of the recent messages, that the company was working towards “safeguarding investors’ interests”. No sign of any such activity. On the other hand, market makers have acquired a freehand to treat this share as they wish. What exactly is happening? Really miserable feeling to watch this kind of decline in the sp, while the company is making good progress in developing and marketing new therapies for oncological and immunological conditions.
Has the management got to say anything about this poor sp? Finally, being remotely helpful, can this low low valuation trigger interest in M&A activity?
Speaking to CNBC at the World Economic Forum in Davos, Switzerland, on Tuesday, Winters said Washington and Beijing are now “pretty interlinked” and that for any president to “aggressively disentangle” would be bad for the U.S., Chinese and global economies.
https://www.cnbc.com/2024/01/16/stanchart-trump-is-transactional-but-may-not-rock-the-boat-on-china.html
Only one trade this morning…..v unusual.
ITP is one of the haematological indications. Www search also brings up articles and news items mentioning many other immunological and haematological malignant conditions. It would have helped us if the company reiterates which are the conditions where Savlo is being developed as a useful therapy .
Searching the www suggests ITP has a prevalence of 9.5 per 100k people…..and it appears to be global rather than concentrated in certain markets…..more importantly, the condition persists for many years with an 80% survival after 5 years…hence the pharma co just needs to get to the patient for a multi year treatment plan.
You would think this would meet criteria to attract a global partner.
There must be much wider market for Sovleplenib as it has been developed for treating autoimmune conditions and haematological malignancies like lymphomas. It will be interesting to watch if the company can get another major player to collaborate, if required.
Amazing, still under price when Takeda deal was announced, curve on interest rates looks encouraging as does US relations with China (at the moment)
M& A continues at a pace with GSK acquisition this week - got to be in it to win it !
Yes some positive news…slightly behind schedule, but priority review will help get this to market in 2024 (approval in June/July?)
They did also promise an NDA for Amdizalisib in 2023….they have not given a trial result for that as yet…..to be confirmed whether that has been a positive result….the P1/2 trial numbers were very small so may not have been that representative of the larger Ph2 registration study….in which case it will be a full ph3 or deprioritised….
First piece of good news for the new year!
NMPA has accepted NDA for Sovleplenib for treatment of adult patients with primary immune thrombocytopenia, for review and granted priority review. As we are aware, HCM has been developing Sovleplenib for the treatment of hematological malignancies and immune diseases.
All a bit strange really, even got Cramer on the case now lol
https://www.cnbc.com/2024/01/05/cramer-names-biopharma-companies-as-industry-mergers-start-to-accrue.html
What about proposing a share buy back with spare cash ?
Can buyback boom revive the FTSE 100?
https://www.thisismoney.co.uk/money/investing/article-12931451/Can-buyback-boom-revive-FTSE-100.html
a pretty poor session for pharma in hk.
hcm only down 3%
innovent -7
beigene -9
a big 6 months for fru*****inib coming up……eu and japan approval. china approval of gastric cancer snda…..and the small matter of the royalties from early us sales.
Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million
Insilico grants Italy’s Menarini Group, the global rights to develop and commercialise a novel small molecule inhibitor, as a potential treatment for hormone-sensitive cancers
https://www.scmp.com/business/banking-finance/article/3247263/hong-kong-based-ai-driven-company-sells-potential-breast-cancer-drug-deal-whose-value-could-exceed
FTSE private takeovers will continue 'unless action is taken', analysts warn
The 'relentless' pace of delisting and takeovers by foreign buyers will continue if urgent action to incentivise UK stock ownership is not taken, a senior analyst has warned.
https://www.thisismoney.co.uk/money/markets/article-12921859/FTSE-private-takeovers-continue-unless-action-taken-analysts-warn.html?ito=email_share_article-top
AZ has signed another Chinese deal with Allorion (operates in China and US, but appears to be unlisted in US). The deal looks similar to that struck with HCM for Savo. A new EGFR drug will be developed by AZ in return for staged milestone payments and future royalties.